Tilray Medical expands medical cannabis portfolio in Australia

Tilray (TLRY) Medical announced its largest portfolio expansion in Australia to date. The expanded medical cannabis offering reinforces Tilray Medical’s long-term commitment to the Australian market and supports increased patient access to regulated, clinically supported medical cannabis products. Tilray Medical has operated in Australia for several years, supplying EU-GMP certified medical cannabis through established prescriber, pharmacy, and clinical distribution channels. This latest expansion represents a scaled increase in Tilray’s local portfolio aligned with rising demand across Australia’s regulated medical system and Tilray’s continued commitment to supply reliable and compliant medical cannabis. Over the coming months, Tilray Medical Australia will expand its medical cannabis portfolio with the introduction of new products across multiple formats under its Redecan and Good Supply brands, further enhancing treatment options for healthcare professionals and patients. The Redecan portfolio will include medical cannabis flower, extracts, vapes, and pastilles, while Good Supply will introduce new medical cannabis flower offerings, broadening access to high-potency, patient-focused medical cannabis solutions.